Karyopharm Therapeutics Business Summary

Karyopharm Therapeutics Inc. (KPTI) is a commercial-stage biopharmaceutical company that generates revenue primarily through the U.S. commercialization and international licensing of its first-in-class Selective Inhibitor of Nuclear Export (SINE) compound, XPOVIO (selinexor). For the 2026 fiscal year, the company has projected total revenue between $130 million and $150 million, driven by XPOVIO sales in multiple myeloma and diffuse large B-cell lymphoma (DLBCL), alongside royalty and milestone payments from global partners such as the Menarini Group and Antengene. The company’s business segments are concentrated in hematologic and solid tumor oncology, with 2026 serving as a transformative year for pipeline expansion into myelofibrosis and endometrial cancer following pivotal Phase 3 readouts. Karyopharm competes directly with oncology giants including Bristol Myers Squibb, Johnson & Johnson, and Pfizer. It maintains a unique market position as the leader in nuclear transport inhibition, offering the only oral XPO1 inhibitor that serves as a high-potency alternative for patients who have exhausted standard-of-care proteasome inhibitors and immunomodulatory drugs. Founded in 2008 by Dr. Sharon Shacham and Dr. Michael G. Kauffman, Karyopharm is currently led by President and CEO Richard Paulson, an industry veteran who previously served as Executive Vice President at Ipsen Pharmaceuticals and held senior roles at Amgen. The executive leadership includes Chief Financial Officer Lori Macomber, appointed in January 2025, who brings an extensive pedigree from her tenure as CFO of Legend Biotech and leadership positions at Pfizer and Eli Lilly. Clinical development and research are overseen by Chief Medical Officer Dr. Reshma Rangwala, formerly of Genmab and Merck, while commercial strategy is driven by Chief Commercial Officer Sohanya Cheng. The company is governed by a board featuring prominent figures like Lead Director Barry Greene (CEO of Sage Therapeutics) and is backed by institutional investors including Foresite Capital, TPG, and BlackRock, underscoring its established presence in the mid-cap biotechnology sector.